Business
Acumen Pharmaceuticals Reports First Quarter 2025 Financial Results and Business Highlights
Expect to report topline results for ALTITUDE-AD, a Phase 2 study to investigate sabirnetug (ACU193) for the treatment of early Alzheimer’s disease, in late 2026 Cash, cash equivalents and marketable securities of $197.9 million as of March 31, 2025, expected to support current clinical and operational activities into early 2027 Company to host conference call and webcast today at 8:00 a.m. ET NEWTON, Mass., May 13, 2025 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (“Acumen” o
About this update from Acumen Pharmaceuticals, Inc.
[{"type":"image","alt":"Acumen Pharmaceuticals, Inc.","displaySize":"","headline":null,"caption":"Acumen Pharmaceuticals, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":62,"url":"https://media.zenfs.com/en/globenewswire.com/cbb5dd6e9a075046255d7d2e82373879"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/5J.4IvnfhFM_bTHIo4TE3Q--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTg3O2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/cbb5dd6e9a075046255d7d2e82373879","width":300,"height":62}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Expect to report topline results for ALTITUDE-AD, a Phase 2 study to investigate sabirnetug (ACU193) for the treatment of early Alzheimer’s disease, in late 2026","length":161,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":161,"olType":false},{"type":"list","items":[{"val":[{"type":"text","content":"Cash, cash equivalents and marketable securities of $197.9 million as of March 31, 2025, expected to support current clinical and operational activities into early 2027 ","length":168,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":168,"olType":false},{"type":"list","items":[{"val":[{"type":"text","content":"Company to host conference call and webcast today at 8:00 a.m. ET ","length":65,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":65,"olType":false},{"type":"text","content":"NEWTON, Mass., May 13, 2025 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (“Acumen” or the “Company”), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer’s disease (AD), today reported financial results for the first quarter of 2025 and provided a business update.","length":393,"tagName":"p"},{"type":"text","content":"“In the first quarter of 2025, Acumen’s strong execution continued to build on the momentum achieved in 2024. ALTITUDE-AD, our Phase 2 study investigating the efficacy, safety and tolerability of sabirnetug for the treatment of early AD, is fully enrolled and we expect topline results in late 2026,” said Daniel O’Connell, Chief Executive Officer of Acumen. “This sizable 542-participant study enrolled quickly, a testament to the interest in sabirnetug’s high selectivity for toxic amyloid beta oligomers...